OS Therapies’ (OSTX) “Buy” Rating Reiterated at D. Boral Capital

OS Therapies (NYSE:OSTX)‘s stock had its “buy” rating restated by equities research analysts at D. Boral Capital in a research note issued to investors on Monday,Benzinga reports. They currently have a $20.00 target price on the stock.

Several other brokerages also recently weighed in on OSTX. Maxim Group lifted their target price on OS Therapies from $8.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday, January 16th. Lake Street Capital began coverage on shares of OS Therapies in a research note on Wednesday, April 2nd. They issued a “buy” rating and a $19.00 price objective on the stock. Three analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $18.00.

OS Therapies Price Performance

OSTX stock opened at $1.40 on Monday. OS Therapies has a 12-month low of $1.26 and a 12-month high of $7.00. The stock has a 50-day moving average price of $1.77 and a two-hundred day moving average price of $2.67.

Insider Buying and Selling

In other OS Therapies news, major shareholder Shalom Auerbach sold 100,000 shares of the stock in a transaction on Friday, February 14th. The shares were sold at an average price of $2.84, for a total value of $284,000.00. Following the completion of the sale, the insider now directly owns 2,431,211 shares of the company’s stock, valued at $6,904,639.24. This represents a 3.95 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 13.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in OS Therapies stock. Virtu Financial LLC acquired a new position in OS Therapies Inc (NYSE:OSTX) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 10,045 shares of the company’s stock, valued at approximately $28,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.